Literature DB >> 29802738

The homeodomain transcription factor MEIS1 triggers chemokine expression and is involved in CD8+ T-lymphocyte infiltration in early stage ovarian cancer.

Athanasios Karapetsas1, Maria Tokamani1, Christos Evangelou1, Raphael Sandaltzopoulos1.   

Abstract

CD8+ T-lymphocytes infiltration is a favorable prognostic marker in ovarian cancer. Recently we identified MEIS1 as a gene overexpressed in early stage ovarian tumors enriched for CD8+ T-cells. Here, we report the molecular mechanism of the homeodomain transcription factor MEIS1 in lymphocyte recruitment. We validated that MEIS1 expression is a positive predictor of CD8+ T cells in early stage ovarian cancer. We showed that MEIS1 induces the expression of CCL18, CCL4, CXCL7, CCL5, CXCL1, and IL8 chemokines in cancer cells followed by their secretion in the culture medium ultimately triggering CD8+ T-lymphocyte recruitment in vitro. Knock down of MEIS1 expression by siRNA resulted in downregulation of these chemokines. We verified that MEIS1 binds to the promoters of chemokine genes, both in vitro and in vivo. We also showed that the expression levels of MEIS1 correlated tightly with the mRNA levels of chemokines CCL4 and CCL18 in early stage ovarian cancer patient samples and served as a positive prognostic marker, as shown by Kaplan-Meyer survival analysis. In conclusion, we propose that MEIS1 plays a pivotal role in the regulatory circuitry governing T-cell chemo-attraction during the early stages of ovarian cancer.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  MEIS1; chemokine antibody arrays; chemotaxis; chromatin immunoprecipitation; electrophoretic mobility shift assay; ovarian cancer

Mesh:

Substances:

Year:  2018        PMID: 29802738     DOI: 10.1002/mc.22840

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  7 in total

1.  Serum Chemokine CXCL7 as a Diagnostic Biomarker for Colorectal Cancer.

Authors:  Longhai Li; Lihua Zhang; Yu Tian; Ting Zhang; Guangliang Duan; Yankui Liu; Yuan Yin; Dong Hua; Xiaowei Qi; Yong Mao
Journal:  Front Oncol       Date:  2019-10-09       Impact factor: 6.244

2.  Oncogenic and tumor suppressor function of MEIS and associated factors.

Authors:  Birkan Gİrgİn; Medine KaradaĞ-Alpaslan; Fatih KocabaŞ
Journal:  Turk J Biol       Date:  2020-12-14

3.  Prognostic Alternative mRNA Splicing in Adrenocortical Carcinoma.

Authors:  Weiwei Liang; Fangfang Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-12       Impact factor: 5.555

4.  Expression of miRNA-601 and PD-L1 among Iranian Patients with Lung Cancer and Their Relationship with Smoking and Mycoplasma Infection.

Authors:  Mahla Ganjali; Babak Kheirkhah; Kumarss Amini
Journal:  Cell J       Date:  2021-12-29       Impact factor: 2.479

Review 5.  Multifaceted Roles of Chemokine C-X-C Motif Ligand 7 in Inflammatory Diseases and Cancer.

Authors:  Qianmiao Wu; Huaijun Tu; Jian Li
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

Review 6.  CXCL1: Gene, Promoter, Regulation of Expression, mRNA Stability, Regulation of Activity in the Intercellular Space.

Authors:  Jan Korbecki; Katarzyna Barczak; Izabela Gutowska; Dariusz Chlubek; Irena Baranowska-Bosiacka
Journal:  Int J Mol Sci       Date:  2022-01-12       Impact factor: 5.923

7.  A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma.

Authors:  Hao Yang; Liang Zhao; Yang Zhang; Fang-Fang Li
Journal:  Cancer Med       Date:  2021-07-13       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.